Research Analysts Set Expectations for Savara Q1 Earnings

Savara Inc (NASDAQ:SVRA) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Savara in a note issued to investors on Friday, March 28th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

A number of other research firms also recently weighed in on SVRA. Wells Fargo & Company started coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Savara Stock Performance

Savara stock opened at $2.86 on Monday. The company has a market cap of $490.83 million, a PE ratio of -6.65 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 1 year low of $2.26 and a 1 year high of $5.34. The company’s 50-day moving average is $2.72 and its two-hundred day moving average is $3.23.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in shares of Savara by 10.8% during the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after purchasing an additional 264,825 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after acquiring an additional 642,259 shares during the period. Barclays PLC increased its holdings in shares of Savara by 217.5% in the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after acquiring an additional 158,244 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after acquiring an additional 6,330 shares in the last quarter. Finally, State Street Corp raised its position in shares of Savara by 15.7% during the third quarter. State Street Corp now owns 4,138,276 shares of the company’s stock worth $17,546,000 after purchasing an additional 560,242 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.